BMO ARK Genomic Revolution Fund (NEO:ARKG)

Assets	4.40M
Expense Ratio	0.96%
PE Ratio	n/a
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	+4.71%

Volume	614
Open	10.74
Previous Close	11.03
Day's Range	10.68 - 10.74
52-Week Low	8.34
52-Week High	14.10
Beta	1.64
Holdings	34
Inception Date	Nov 14, 2022

About ARKG

As of July 11, 2025, BMO ARK Genomic Revolution Fund has gone out of business. BMO ARK Genomic Revolution Fund is an exchange traded fund launched by BMO Investments Inc. The fund is managed by ARK Investment Management LLC. The fund invests in public equity markets of global region. It invests in stocks of companies operating across disruptive genomic innovation sectors. It invests in growth and value stocks of companies across diversified market capitalization. It employs fundamental analysis to create its portfolio. The fund seeks to benchmark the performance of its portfolio against the MSCI ACWI Health Care Index (C$). BMO ARK Genomic Revolution Fund was formed on November 1, 2022 and is domiciled in Canada.

• Asset Class: Equity
• Category: Theme
• Stock Exchange: Cboe Canada
• Ticker Symbol: ARKG
• Provider: BMO

Performance

ARKG had a total return of 4.71% in the past year, including dividends. Since the fund's inception, the average annual return has been -10.64%.

Top 10 Holdings

60.15% of assets

Name	Symbol	Weight
CRISPR Therapeutics AG	CRSP	9.62%
Tempus AI, Inc.	TEM	9.28%
Twist Bioscience Corporation	TWST	7.38%
Guardant Health, Inc.	GH	6.60%
Recursion Pharmaceuticals, Inc.	RXRX	5.56%
Natera, Inc.	NTRA	5.33%
Adaptive Biotechnologies Corporation	ADPT	4.39%
Personalis, Inc.	PSNL	4.37%
CareDx, Inc.	CDNA	3.85%
Schrödinger, Inc.	SDGR	3.77%

Data Sources: S&P Global Market Intelligence and Finnhub

Historical data is provided by S&P Global Market Intelligence. Several fund data points are also provided by Finnhub.

Last checked:

Aug 13, 2026

Data Sources Report a data error